While AI's role in headline-grabbing discoveries like AlphaFold is celebrated, Anthropic is forging a new path. Through partnerships with the Allen Institute and HHMI, the company is embedding Claude AI into the unglamorous, time-consuming groundwork of research—betting that efficiency gains in data analysis and coordination will compress decades of scientific progress.
Tesla will cease production of its flagship Model S and Model X next quarter, ending an era for its pioneering luxury EVs as it converts factory space to manufacture Optimus humanoid robots, signaling a profound strategic pivot.
With the 2025 tax filing season now open, millions of Americans are looking ahead to their 2026 refunds. We break down how to track your payment, expected wait times, and the potential impact of recent legislation on your bottom line.
As sports betting handles hit record highs, data reveals a stark contrast: the average bettor consistently loses, while disciplined investing in instruments like index funds builds wealth over time.
While Gen Digital's stock has significantly underperformed the broader market, analysts point to robust earnings, solid bookings growth, and raised guidance as reasons for a cautiously optimistic 'Moderate Buy' consensus, despite glaring inconsistencies in quarterly execution.
A new cache of Jeffrey Epstein's emails has implicated former Prince Andrew, his ex-wife Sarah Ferguson, and senior Labour figure Peter Mandelson, revealing intimate correspondence, financial dealings, and raising fresh questions about influence and accountability at the highest levels of British society.
As Kevin Warsh emerges as a frontrunner for Federal Reserve Chair, former colleagues paint a picture of a consensus-seeking listener. But with the Fed facing internal divisions and external pressure, questions remain: Is his collaborative style the steady hand needed, or a potential liability in times of crisis?
Despite a volatile post-earnings reaction, Invesco Ltd. maintains robust analyst support with upgraded ratings and bullish price targets, as the asset manager's strategic moves and inflows fuel optimism.
Despite posting strong quarterly results and outperforming major indices over the past year, U.S. Bancorp's stock is met with a measured 'Moderate Buy' consensus from analysts, highlighting a divergence between performance and sentiment.
From Mussolini's Rome-Berlin Axis to Bush's 'Axis of Evil,' the term has evolved into a potent geopolitical label. Its revival to describe groupings like the 'Axis of Upheaval' reveals how language frames modern conflicts and defines the boundaries of legitimacy in international politics.
While Procter & Gamble's stock has trailed the market over the past year, analysts remain cautiously optimistic. The company's latest earnings reveal a story of resilience amid pricing pressures and shifting consumer demand, leaving investors to weigh its steady guidance against a recent analyst downgrade.
While investors flock to mass-market and electric vehicle stocks, Ferrari's unique strategy of cultivating scarcity and brand prestige has delivered enviable margins and pricing power. With shares well off their highs, analysts debate if now is the time to buy into this iconic automaker for the long haul.
Former UK ambassador to Washington, Peter Mandelson, faces intensifying political and public pressure to relinquish his lifetime seat in the House of Lords following new revelations about his financial and personal ties to the late convicted sex offender Jeffrey Epstein. Prime Minister Keir Starmer has called for his resignation, as documents suggest payments and close correspondence between the two.
While Legend Biotech's CAR-T therapy Carvykti missed Q4 sales estimates, prompting mixed analyst reactions, some firms emphasize its curative potential and view the stock's recent decline as a strategic entry point for investors.
Ardelyx, Inc. (NASDAQ: ARDX) has received significant analyst upgrades, with TD Cowen and Jefferies raising price targets ahead of the company's fourth-quarter results. The optimism centers on the commercial trajectory of its flagship drug, tenapanor, for gastrointestinal and kidney conditions.
Kevin Warsh, a leading candidate for Federal Reserve Chair, has historically framed Bitcoin not as a threat but as a crucial policy signal. His past comments labeling it 'the new gold' for younger investors stand in stark contrast to the cryptocurrency's recent 3% decline, highlighting the volatile intersection of regulatory sentiment and digital asset markets.
Analysts at Stifel have raised their price target for Nurix Therapeutics (NRIX) to $35, maintaining a Buy rating ahead of anticipated 2026 clinical milestones for its lead asset, bexobrutinib. The move comes as Wells Fargo also adjusted its target, highlighting divergent near-term views but shared long-term optimism for the biotech firm.
The $12 trillion asset manager founded by Jack Bogle announced another round of expense reductions across 53 funds, saving investors an estimated $600 million over two years and reinforcing its half-century mission of driving down costs for the everyday investor.
MicroStrategy, the corporate world's largest Bitcoin holder, sees the token's price dip below its average purchase cost for the first time since 2023, testing the resilience of Michael Saylor's high-conviction, leverage-fueled strategy amid a shifting market landscape.
Firm Capital Property Trust (TSE:FCD.UN) delivered a 22% total shareholder return over the past year, buoyed by dividends, despite a more modest share price gain and underlying earnings pressure. The performance highlights the complex dynamics between dividend yield, market sentiment, and fundamental business health in the current real estate investment trust (REIT) landscape.
